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We conducted a genome-wide association study to search for risk alleles associated with Tetralogy of Fallot
(TOF), using a northern European discovery set of 835 cases and 5159 controls. A region on chromosome
12q24 was associated (P 5 1.4 3 1027) and replicated convincingly (P 5 3.9 3 1025) in 798 cases and 2931
controls [per allele odds ratio (OR) 5 1.27 in replication cohort, P 5 7.7 3 10211 in combined populations].
Single nucleotide polymorphisms in the glypican 5 gene on chromosome 13q32 were also associated
(P 5 1.7 3 1027) and replicated convincingly (P 5 1.2 3 1025) in 789 cases and 2927 controls (per allele
OR5 1.31 in replication cohort, P 5 3.03 3 10211 in combined populations). Four additional regions on chro-
mosomes 10, 15 and 16 showed suggestive association accompanied by nominal replication. This study, the
first genome-wide association study of a congenital heart malformation phenotype, provides evidence that
common genetic variation influences the risk of TOF.
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INTRODUCTION
Congenital heart disease (CHD) affects 1% of live births and
is a major source of morbidity and mortality in childhood. Ap-
proximately 20% of CHD occurs in the setting of chromosomal
conditions or multisystem malformation syndromes. Family
studies in the remaining 80% of ‘sporadic’ cases indicate a sig-
nificant complex genetic component to the disease (1). Previous
studies have indicated that rare and de novo copy number vari-
ation in the human genome contribute 5–10% of the population
risk of sporadic CHD (2–5), but genome-wide association
studies (GWAS) assessing the relationship between common
single nucleotide polymorphism (SNP) and CHD risk are yet
to be reported. Tetralogy of Fallot (TOF) is the commonest
form of cyanotic CHD, affecting 3 per 10 000 newborns (6).
Although TOF is usually repaired in infancy with low mortality,
there is substantial late morbidity, in particular from pulmonary
valvular insufficiency and atrial and ventricular arrhythmias.
Population studies suggest a substantial familial recurrence
risk in sporadic, non-syndromic TOF (1,7). We, therefore,
undertook a GWAS to identify common genetic risk factors pre-
disposing to TOF, given the high success of this design over the
past 5 years (8).
RESULTS
Figure 1 shows the genome-wide association results obtained
with two complementary approaches, case/control analysis in
PLINK and family-based analysis in estimation of maternal,
imprinting and interaction effects software (EMIM) (see Mate-
rials and Methods). With PLINK, the strongest signal of asso-
ciation occurred at a group of SNPs on chromosome 12q24
(top SNP rs11065987, P ¼ 4.6 × 1028), with several other
regions, including SNPs on chromosomes 3, 10, 13 and 16
reaching more modest, but suggestive levels of significance
(P ≤ 1 × 1025). Quantile–quantile (QQ) plots (Supplemen-
tary Material, Fig. S1A) indicated a slight inflation in the
genome-wide distribution of test statistics (genomic control in-
flation factor l ¼ 1.076) (9), possibly due to unmodelled popu-
lation substructure. Correction using the top 10 principal
components from EIGENSOFT reduced the genomic control
inflation factor slightly (l ¼ 1.037, Supplementary Material,
Fig. S1B) without affecting the overall results substantially
(rs11065987 remained the top SNP, P ¼ 6.0 × 1028). Correc-
tion using GenABEL resulted in a reduction in the genomic
control factor l to 0.996, with no systematic departure from
the expected line in the resulting QQ plot (Supplementary
Figure 1. Manhattan plots of the genome-wide association results. The top panel (PLINK results) shows the –log10 P-values from the Cochran–Armitage trend
test (for autosomal SNPs) or logistic regression allowing for gender as a covariate (for X-chromosomal SNPs). The bottom panel (EMIM results) shows the
2log10 P-values from the child trend test (autosomal SNPs only). Dashed lines are shown at significance thresholds for suggestive (P ¼ 1 × 1025) and signifi-
cant (P ¼ 5 × 1028) association, respectively.
1474 Human Molecular Genetics, 2013, Vol. 22, No. 7
Material, Fig. S1C). The 12q24 region remained the strongest
signal of association (Table 1, Supplementary Material,
Table S1) with a slight decrease in overall significance
(P ¼ 1.4 × 1027 at the top SNP, rs11065987).
The results from EMIM were found to be broadly concord-
ant with those from PLINK (Supplementary Material, Fig. S2),
although this fact is visually less obvious in Figure 1 due to
slight differences in the precise levels of significance achieved
at the top ranking SNPs. In EMIM, the strongest signal of as-
sociation was seen on chromosome 13q32 (rs7982677, P ¼
7.4 × 1028, reducing to P ¼ 1.7 × 1027 with correction for
the observed genomic control inflation factor of 1.057).
Summary-level results of the GWAS in the discovery cohort
are available at http://www.staff.ncl.ac.uk/heather.cordell/
TOFGWAS.html.
We attempted to replicate all association signals passing
nominal significance P ≤ 1 × 1025 (Table 1, Supplementary
Material, Table S1) using an additional cohort of UK,
Dutch and Canadian TOF cases and controls of northern
European ancestry. The chromosome 12q24 region strongly
replicated (P ¼ 9.7 × 1026 at rs233722; P ¼ 3.9 × 1025 at
rs11065987; combined discovery and replication P ¼ 7.7 ×
10211 at rs11065987) with a per allele odds ratio (OR)
for TOF of 1.27 [95% CI (1.13–1.42)] in the replication
cohort. The chromosome 13q32 region also strongly replicated
(P ¼ 1.2 × 1025 at rs7982677, combined discovery and
replication P ¼ 3.03 × 10211) with a per allele OR for TOF
of 1.31 [95% CI (1.16–1.48)] in the replication cohort.
More modest levels of replication were seen at two separate
regions of chromosome 10 (P ¼ 0.0018 at rs2388896, P ¼
0.0062 at rs2228638) and on chromosomes 15 (P ¼ 0.043 at
rs12593223) and 16 (P ¼ 0.033 at rs6499100).
Figure 2 shows LocusZoom plots (10) from the discovery
analysis for the two most strongly replicating loci, including
colour codings of the linkage disequilibrium (LD) values
between the top scoring SNPs. We used stepwise logistic re-
gression to determine the extent to which the association
signal in the chromosome 12q24 region (which was supported
by a large number of SNPs spanning 1.4 Mb) could be
accounted for by the top SNP. In the discovery cohort, inclu-
sion of rs11065987 as a covariate reduced the signal of asso-
ciation to P . 1023 in the vicinity (Supplementary Material,
Fig. S3), suggesting that LD with rs11065987 could account
for most of the strong associations seen at SNPs in this
region. In the replication cohort, only two SNPs (rs233722
and rs233716) retained nominal significance (P , 0.05) once
rs11065987 had been included as a covariate, whereas only
one SNP (rs11065987) retained nominal significance once
rs233722 had been included as a covariate (Supplementary
Material, Table S2), suggesting again that the association
signal could largely be accounted for by a single variant
within the LD block.
To further refine the association signal at chromosome
12q24, we carried out imputation in the discovery cohort
within the 5 Mb region centred around rs11065987. Although
the association signal was supported by results from a number
of imputed SNPs (Supplementary Material, Fig. S4), none
showed significantly stronger association than had already
been seen at our top genotyped SNP, rs11065987. T
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Figure 2. LocusZoom plots for the replicating loci on chromosomes 12 (PLINK results) and 13 (EMIM results). The colour coding indicates the degree of LD of
each SNP with the named index SNP (shown as a purple diamond), as estimated from the HapMap CEU population.
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DISCUSSION
Our study provides compelling evidence that common genetic
variation influences the risk of CHD. The top SNPs on chromo-
some 12 implicated by our discovery and replication analyses
(P ¼ 7.7 × 10211) are located within a large LD block on
12q24. This region has previously been associated with a
variety of complex genetic conditions, including type 1 diabetes
(11), celiac disease (12), coronary artery disease (13), rheuma-
toid arthritis (14), systemic lupus erythematosus (15) multiple
sclerosis (16) and with blood platelet count (13). The risk
alleles at the top SNPs in our analysis all lie on a common
(40% frequency in individuals of White European ancestry)
1.6 Mb haplotype at chromosome 12q24, containing 15 genes,
that spans our associated interval (Fig. 2 and Supplementary
Material, Table S3). A previous analysis (13) provided strong
evidence that the haplotype has undergone recent positive selec-
tion in individuals of European ancestry. For all conditions asso-
ciated with this haplotype described thus far, including TOF, the
alleles conferring increased risk at the associated SNPs are the
derived alleles, whose frequencies have increased in Europeans
by a selective sweep (starting around 3000 years ago). Our
chromosome 12 results add to the remarkable disease pleiotropy
associated with variation in the 12q24 region of the human
genome.
Imputation analysis in our discovery cohort indicated that,
although our association signal could be driven by any one
of a number of imputed SNPs, none show significantly stron-
ger association than is already seen at our top genotyped SNP
(rs11065987). Further interrogation of this region, ideally in
non-European cohorts, showing varying LD patterns, will be
required to further refine the association signal. Within the
12q24 region, the strongest candidate gene is tyrosine-protein
phosphatase non-receptor type 11 (PTPN11), a regulator of
Ras/mitogen-associated protein kinase signalling. Activating
mutations of PTPN11 are a cause of Noonan’s syndrome
(17), a Mendelian multisystem disorder in which malformation
of the cardiac outflow tract is a typical feature. Association
between a SNP in PTPN11 (rs11066320) and TOF was previ-
ously demonstrated (18) in a candidate gene study using a
family-based association analysis approach on a set of 754
TOF cases that partially overlap with the set of cases described
here. Further research will be necessary to investigate the hy-
pothesis that the SNP association we have observed in this
region results from upregulation of the activity of PTPN11
and the magnitude of effect compared with that of the
gain-of-function mutations that lead to Noonan’s syndrome.
The observation of association between TOF and an evolu-
tionarily selected haplotype at 12q24 raises some intriguing
questions. In contrast with conditions of adult onset, such as cor-
onary artery disease and rheumatoid arthritis, previously shown
to be associated with 12q24 SNPs, the condition on which we
have focussed carries substantial early mortality that signifi-
cantly impacts reproductive fitness. Prior to the modern
cardiac surgical era, mortality from TOF before the age of 10
years was around 80%. Given this, it might be expected that
any variant conferring even a modest additional risk of TOF
would have been eliminated, or driven to very low allele fre-
quency, by natural selection. The nature of the selection event
responsible for the emergence of the pleiotropic 12q24 risk
haplotype is unknown, although given the role of genes in the
region in T-cell function, it is thought likely to relate to
enhanced resistance to infectious disease at a time of increased
human population density in Europe (13). Our data on a
childhood phenotype that until recently was highly lethal
illustrate the impact of immunity as a selective force in
human evolution—as has been recently shown for the effects
of Y chromosome haplogroups on immune function and athero-
sclerosis risk (19).
Our findings on chromosome 13 [rs7982677 at 13q32, OR ¼
1.31, 95% CI ¼ (1.16–1.48), P ¼ 3.03 × 10211] and in two
separate regions of chromosome 10 [rs2388896 at 10p14,
OR ¼ 0.83, 95% CI ¼ (0.74, 0.93), P ¼ 8.55 × 1028 and
rs2228638 at 10p11.2, OR ¼ 1.28, 95% CI ¼ (1.07, 1.53),
P ¼ 2.05 × 1027] are also significant. The top SNPs in the
13q32 region lie in intron 7 of the GPC5 gene that encodes
for glypican 5. Glypicans are heparan sulphate proteoglycans
that are bound to the outer surface of the plasma membrane
by a glycosyl-phosphatidylinositol anchor. There are six
members of the glypican family in mammals, and they serve
as regulators of key developmental signalling pathways, includ-
ing the Wnt, Hedgehog, fibroblast growth factor and bone mor-
phogenetic protein pathways (20). Glypicans are, therefore,
strong candidate genes for involvement in cellular growth
control and morphogenesis during heart development. GPC5
has eight exons and occupies 1.42 Mb at chromosome
13p32. The seventh intron, which harbours our top SNPs, is
735 Kb long and contains three putative non-coding transcripts,
none of which are overlapped by our top SNPs. SNPs in GPC5
have been associated with the risk of nephrotic syndrome (21),
with protection from sudden cardiac arrest (22) and with higher
risks of lung cancer and multiple sclerosis (23,24). GPC5 is
among the genes deleted in a subset of patients with 13q deletion
syndrome, a multisystem disorder (typically characterized by
holoprosencephaly) in which CHD can occur. In a French
cohort of 12 patients with 13q deletion, 2 had TOF, and
GPC5 was deleted in both of these patients (25); single patients
with 13q deletion and TOF have been reported by two other
groups (26,27). Defects in genes encoding for other members
of the glypican protein family have been linked to cardiac mal-
formation syndromes. CHD is common in Simpson–Golabi–
Behmel syndrome, the condition associated with GPC3 muta-
tion (28), and has been reported in omodysplasia, the condition
associated with GPC6 mutation (29). Given the large size of the
genomic interval spanned by theGPC5 gene, it seems likely that
the association we have observed here results from an effect on
the function of GPC5 itself, rather than a neighbouring gene.
On chromosome 10, rs2388896 lies in a gene desert [the
nearest gene, GATA-binding transcription factor protein
family, lies some 0.8 Mb distant], whereas rs2228638 is a non-
synonymous coding SNP that results in the substitution of Iso-
leucine for Valine at position 733 of the neuropilin-1 protein,
which is encoded by the gene NRP1. Neuropilin-1 is a receptor
for ligands from the vascular endothelial growth factor and
semaphorin families that is essential for septation of the
cardiac outflow tract (30). Neuropilin-1 has an important func-
tion in normal arteriovenous patterning (31), and disruption of
endothelial neuropilin-1 leads to cardiac outflow tract defects
similar to those seen in human DiGeorge syndrome (in which
context TOF is a frequent occurrence) (32). Further research
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will be required to identify whether the association is due to a
functional effect of rs2228638 or of some other variant in LD.
In conclusion, our study has identified two regions (12q24
and 13q32) that are strongly and replicably associated with
TOF. As far as we are aware, this is the first genome-wide
study focussing on SNP associations to have been reported
in CHD. Pooling patient resources from several international
groups was required to achieve sufficient numbers of cases
for adequate power to detect and replicate a number of
genetic effects; however, studies of commoner diseases have
emphasized the importance of very large cohorts of cases
and controls. The present relatively small GWAS cohort has
in all likelihood detected only the strongest genome-wide
influences on TOF risk. Our results suggest that larger inter-
national collaborative studies have the potential to discover
additional significantly associated loci.
Complete summary association results from the GWAS
component of our study (the EIGENSOFT corrected results)
are available to interested researchers by contacting the corre-
sponding author.
MATERIALS AND METHODS
Study subjects and genotyping
For the initial (discovery) phase, individuals with TOF of north-
ern European ancestry, together with their parents and affected
siblings (when available), were recruited from multiple centres
in Newcastle, Leeds, Bristol, Liverpool, Oxford, Nottingham
and Leicester (all UK), Leuven (Belgium), Erlangen
(Germany) and Sydney (Australia). Ethical approval was
obtained from the local institutional review boards at each of
the participating centres prior to blood or saliva sample collec-
tions, and informed consent was obtained from all subjects, or
from their parents/legal guardians, if the patient was a child too
young to provide consent him/herself. Patients who exhibited
clinical features of recognized malformation syndromes, devel-
opmental abnormalities or learning difficulties were excluded
from the study. All samples were screened for the known
22q11.2 deletion associated with TOF (33,34) using multiplex
ligation-dependent probe amplification (MRC-Holland) and
excluded, if the deletion was present. SNP genotyping was
carried out at the Centre National de Genotypage (Evry Cedex,
France) using the Illumina 660wQUAD array, and the genotypes
were compared with genotype data for UK population-based con-
trols (5667 individuals genotyped on the Illumina 1.2M chip)
obtained from the Wellcome Trust Case Control Consortium 2
(WTCCC2) (https://ccc.wtccc.org.uk/ccc2).
For the replication phase, individuals with TOF of self-
reported Caucasian ancestry were recruited from Oxford, Not-
tingham, Newcastle, The Netherlands and Canada. Five
hundred and fifteen Dutch TOF cases were identified from
the Netherlands national registry and DNA bank of patients
with CHD (CONCOR), the design of which has been previ-
ously described (35). One hundred and forty-four Canadian
TOF cases, together with Canadian controls of self-reported
Caucasian ancestry, were obtained from the SickKids Heart
Centre Biobank, an Ontario province-wide biorepository for
CHD. These replication samples were genotyped at the
Centre National de Genotypage using Sequenom matrix-
assisted laser desorption/ionization—time of flight. Additional
UK population-based control data for the replication were
obtained from the TwinsUK resource (http://www.twinsuk.a
c.uk), an adult twin registry comprising 12 000 (predominantly
female) twins. Genotype data for 3512 twin individuals (gen-
otyped using the Illumina 610K array) were obtained from the
Department of Twin Research and Genetic Epidemiology at
King’s College, London. Only the first twin from each pair
of genotyped twins (2603 unrelated individuals) was used in
the current study.
Statistical analysis
Following stringent quality control (QC) procedures (see
below), the final discovery dataset for analysis consisted of
835 unrelated cases and 5159 controls (plus 717 additional
family members, including both parents for 293 of the
cases), genotyped at 516 131 autosomal and X-chromosomal
SNPs. The primary analysis performed was a case/control ana-
lysis of the 835 unrelated cases and 5159 controls using either
the Cochran–Armitage trend test (for autosomal SNPs) or lo-
gistic regression, allowing for gender as a covariate (for X-
chromosomal SNPs), using the software PLINK (36). We
also used two alternative approaches designed to correct for
possible population stratification: Firstly, we used the
‘smartpca’ routine of the EIGENSOFT package (37) to calcu-
late the top 10 principal components that were entered as cov-
ariates into a logistic regression analysis of each SNP across
the genome. Secondly, we analysed each SNP using a score
test from a linear mixed model (38), allowing for possible re-
latedness between individuals via consideration of their
genome-wide estimated kinship coefficients, using the
‘mmscore’ function in the R package GenABEL (39). This ap-
proach has been previously proposed as a means of correcting
for unknown population structure between apparently unre-
lated individuals in a genome-wide association study (40).
In addition to the case/control analyses, we also performed a
family-based association analysis (of autosomal SNPs only) of
all cases, their relatives and controls using the software
package EMIM (41). EMIM is primarily designed for the in-
vestigation of complex genetic effects, including maternal
genotype effects, maternal–fetal interactions and imprinting
(41). In this instance, we used the ‘child trend’ model in
EMIM to model only an effect of the child’s (case’s) own
genotype. The resulting analysis was, thus, conceptually
similar to the case/control analysis we had performed in
PLINK, but with the advantage of allowing additional infor-
mation from parental genotypes to be incorporated, where
available.
The replication cohort (after QC) consisted of 798 cases and
2931 controls. Genotypes were analysed using logistic regres-
sion in PLINK, allowing for two levels of nationality (British/
Dutch or Canadian) as a covariate. P-values for association in
the combined (discovery and replication) datasets were calcu-
lated using Fisher’s trend approach for combining P-values as
implemented in the online software MetaP (http://www.svap
roject.org/metap.php).
To further refine the association signal at chromosome
12q24, we carried out imputation in the discovery cohort
within the 5 Mb region centred around rs11065987. We used
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the program IMPUTE version 2 (42) with data from the 1000
Genomes Project (Phase I interim data, released June 2011) as
a reference panel. Data at 11 208 SNPs passing post-
imputation QC (from an original 56 637 imputed SNPs)
were analysed using the program SNPTEST to test for associ-
ation with disease status.
QC procedures
Discovery cohort
We used stringent QC checks to ensure that only high-quality
data were included in the final analysis. QC procedures were
carried out in PLINK version 1.07 (36) with visualization per-
formed in R (http://www.r-project.org/). For the current study,
genotype data were generated at 557 124 SNPs across the
genome for 1733 individuals (comprising 913 TOF cases plus
a number of unaffected relatives). We excluded individuals
with genotype call rates,98.78% and average heterozygosities
outside the range (0.310, 0.336) (based on consideration of
540 241 autosomal SNPs passing loose QC, namely successful-
ly genotyped in .95% of individuals and with a Hardy–Wein-
berg equilibrium test P-value .1028). These exclusion
thresholds were chosen based on visual inspection of the call
rates and heterozygosities (Supplementary Material, Fig. S5)
to retain the majority of individuals, whereas excluding outlying
individuals.
We generated a smaller set of 41 692 autosomal SNPs (suc-
cessfully genotyped in .95% of individuals, with a Hardy–
Weinberg equilibrium test P-value .1028, with minor allele
frequencies .0.4 and pruned to show low levels of LD using
the PLINK command ‘–indep 50 5 2’) that were used to
check relationships/sample duplications and ethnicities.
Genome-wide identity-by-descent (IBD) sharing was calcu-
lated using the ‘–Z-genome’ command in PLINK, and one of
each pair of related individuals (mean proportion of alleles
shared IBD .0.1) was excluded. Multidimensional scaling of
our samples together with 210 unrelated Phase II HapMap
(43) individuals from 4 populations [Utah residents with ances-
try from northern and western Europe (CEU), Japanese in
Tokyo, Japan, Han Chinese in Beijing, China and Yoruba in
Ibadan, Nigeria] (genotyped at same set of 41 692 autosomal
SNPs) was performed and identified 33 individuals in our
study who did not cluster with the CEU samples, suggesting
non-European ancestry (Supplementary Material, Fig. S6).
These individuals were excluded.
We used the ‘–check-sex’ option in PLINK to check (based
on the average X chromosomal heterozygosity) that the gender
of our samples matched its expected value and excluded
samples for which we were unable to resolve inconsistencies.
Following QC, we were left with 835 unrelated TOF cases
(plus 717 additional family members), whose genotypes were
compared with genotype data from 5159 UK population-based
controls obtained from the WTCCC2 (https://ccc.wtccc.org.
uk/ccc2). These controls comprised 2673 samples from the
1958 British Birth Cohort study (58C) and 2486 National
Blood Service (NBS) samples (selected from an initially gen-
otyped set of 2930 58C samples and 2737 NBS samples). We
excluded the same controls as had been excluded in the
WTCCC2 (44) and WTCCC3 (45) studies, plus an additional
four controls that we found to be outliers, following a principal
components analysis using the ‘smartpca’ routine of the
EIGENSOFT package (37).
Within each of the case and control cohorts, we excluded
any SNPs with minor allele frequencies ,0.01 that were suc-
cessfully genotyped in ,95% of individuals or that had a
Hardy–Weinberg equilibrium test P-value ,1028. Within
the two control cohorts, we also implemented SNP exclusions
recommended by WTCCC2 relating to a measure of the stat-
istical information in the genotype data about allele frequency
(exclude if ,0.975), missingness (exclude if .2% missing
genotypes) and plate effects (exclude if P-value from an
n-degree of freedom test of plate association ,1 × 1025).
Within the TOF case cohort (for which a number of family
members had been genotyped), we also excluded SNPs
showing .10% Mendelian inheritance errors.
Following an initial association analysis, visual inspection
of intensity cluster plots (46) was performed for all SNPs
showing nominal P-value ,1025, and only those SNPs for
which the genotype calls appeared reliable (well clustered
into three distinct groups) were taken forward for replication.
All SNPs reported here passed this visual inspection of
intensity cluster plots in the discovery cohort, indicating that
genotype data and, thus, results at these SNPs could be consid-
ered reliable.
Replication cohort
QC was also performed on the genotype data from the
TwinsUK replication sample. From the 2603 first twins con-
sidered, we excluded 43 showing genotype call rates ,99%
and average heterozygosities outside the range (0.312,
0.331) (based on the consideration of 576 610 autosomal
SNPs passing loose QC, namely: successfully genotyped in
.95% of individuals and with a Hardy–Weinberg equilibrium
test P-value .1028). These exclusion thresholds were chosen
based on visual inspection of the call rates and heterozygos-
ities. We carried out testing of relationships/sample duplica-
tions and ethnicity using the same approach as described
above for the TOF cohort and excluded first twins who did
not cluster with the CEU HapMap samples and one of each
pair of first twins who showed high IBD sharing (mean pro-
portion of alleles IBD .0.05). This resulted in a final set of
2547 TwinsUK controls to be used in the replication study.
Post-imputation QC
We used the program IMPUTE version 2 (42) to carry out im-
putation in the discovery cohort within the 5 Mb region
centred around rs11065987. Data from the 1000 Genomes
Project (47) (Phase I interim data, released June 2011) were
used as a reference panel. Post-imputation QC involved ex-
cluding any SNPs likely to be poorly imputed (specifically
those with an ‘info’ score ,0.5 or with minor allele frequency
in controls ,0.01). Data at 11 208 SNPs passing post-
imputation QC (from an original 56 637 imputed SNPs)
were analysed in the program SNPTEST version 2.1.1 (46),
using the ‘-method ml’ option (a Newton–Raphson algorithm
that maximizes the missing data likelihood) to account for
genotype uncertainty.
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